Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021 2024
Previous Archive
31 March 2020 | Story Leonie Bolleurs | Photo Supplied
UFS Covid-19 vaccine research team
Prof Robert Bragg and members of the Veterinary Biotechnology research group believe that finding a vaccine for COVID-19 will not be a ‘quick fix’. From the left are: Prof Bragg, Samantha McCarlie, Liese Kilian, and Dr Charlotte Boucher-van Jaarsveld. The photo was taken during the World Veterinary Poultry Association congress in Thailand in 2019.

On 31 March 2020, there were 804 061 coronavirus cases and 39 064 deaths globally due to the outbreak. According to media reports, there is still no licensed vaccine for COVID-2019 – the cause of our current global health emergency.  

Prof Robert Bragg, researcher at the University of the Free State (UFS), says this is without a doubt the most pressing research need in the world today. 

The Veterinary Biotechnology research group in the Department of Microbial, Biochemical, and Food Biotechnology at the UFS recently submitted an article for publication on the design of a possible COVID-19 vaccine, based on work they have done on infectious bronchitis virus (also a coronavirus). The article, authored by the group of which Prof Bragg is a member, is titled: A sub-unit vaccine produced in 'Yarrowia lipolytica' against COVID-19: Lessons learnt from infectious bronchitis virus. 

The research group, consisting of researchers and postgraduate students, is mostly looking at strategies for improved disease control, mainly in avian species, through vaccine development, treatment, and biosecurity.

Prof Bragg says their main aim with this study was to get the research out there so that the bigger pharmaceutical companies could take up the design of a possible COVID-19 vaccine and assist with the development of a vaccine. 

He says the research group’s role in this lengthy process would be to express the protein, which could be used in the development of a possible vaccine. “Thereafter, it will have to be taken up by a vaccine manufacturer to get the vaccine made and to the market.”

Developing a vaccine
Liese Kilian, a member of the research group, finished writing up her MSc thesis in Microbiology in the UFS Department of Microbial, Biochemical, and Food Biotechnology in December 2019 – the same time that COVID-19 originated in China. She has been working on the development of an edible sub-unit vaccine against the infectious bronchitis virus (IBV), which is a widespread avian coronavirus. This virus is specific to poultry and is different from COVID-19. 

Kilian’s project was conducted under the supervision of Prof Bragg and Dr Charlotte Boucher-van Jaarsveld. Dr Boucher-van Jaarsveld is a research fellow in the university’s Department of Microbial, Biochemical and Food Biotechnology.

Kilian, with the assistance of Samantha Mc Carlie, currently a master’s student in the research group, substituted the genetic code of the IBV with the genetic code of the COVID-19 virus, which were already published at that stage. Thus, a gene for the development of a possible sub-unit vaccine against the S1 spike protein of COVID-19 was developed for expression in the same yeast strain used to express the spike protein of IBV. A sub-unit vaccine can be described as part of a pathogen, triggering an immune response against the pathogen from which it is derived.

After Killian successfully developed the gene for this study, she expressed the S1 spike protein of the IBV in a yeast-based expression system developed by the research group. Dr Boucher-van Jaarsveld says this simply means that the yeast takes up the foreign genetic material (viral gene) into its own genetic make-up and makes more of this protein as if it is part of the yeast’s normal material. 

“The images of COVID-19 are being shown constantly in the media and the ‘spikes’ can be seen on all of these images. These spikes are very typical for all coronaviruses and there is some level of similarity between the structure of these spikes in many of the coronaviruses,” Prof Bragg adds.

According to the World Health Organisation, the spike protein is a promising candidate for a sub-unit vaccine due to its immunogenicity and safety, as well as manufacturing and stability considerations during large-scale development.

Prof Bragg says there are many different expression systems that are widely used. Producing the sub-unit vaccine in a yeast species is beneficial for the work they are doing. A yeast expression system is favourable as large-scale production, is less expensive compared to mammalian cell lines, and can be applied as an edible vaccine.

“The technology to grow massive volumes of yeast are also very well established. This, after all, is how beer is made!” Prof Bragg says. Dr Boucher-van Jaarsveld adds: “The expression of an antigen is not necessarily just geared towards vaccines but can also be used in the development of diagnostic tests to screen populations for infections.”

Working with other researchers
“Now that the situation is all but out of control, we maybe need to investigate the possibilities of working with other key researchers at the UFS as well as other universities in South Africa to develop the vaccine or diagnostic reagents locally. Discussions on this aspect are already underway.”

Several other universities in South Africa are also working to find a cure for the virus. Government availed funding for more research on the matter. According to Higher Education, Science and Technology Minister, Blade Nzimande, the University of Cape Town, the Council for Scientific and Industrial Research, as well as the Vaccines Institute of Southern Africa are working on the development of a vaccine.

Prof Bragg expressed the hope of obtaining funding for this work. “Because without funding, we will not be able to do anything with this data,” he says. They are currently investigating different funding options. 

“The sooner we start on the development of a vaccine, the sooner there will be one, but it will not be a ‘quick fix’. It must be stressed that, even if vaccine development is fast-tracked through the regulatory bodies, it will take many months (if not years) to move from the laboratory to the first human experimentation. It will take even longer before any human vaccine can be rolled out,” says Prof Bragg.



News Archive

UFS establishes links with the University of Ghent
2007-11-15

The University of the Free State (UFS) recently formalised its co-operation ties with the University of Ghent in Belgium. The two universities signed a memorandum of understanding during the Accenta Trade Fair, an annual event that incorporates activities such as business seminars, cultural events and exhibitions.

The signing of the memorandum of understanding took place via a live video conference linking the two institutions of higher learning.

“It was a wonderful moment because, after signing the memorandum of understanding on the Main Campus in Bloemfontein, the Rector and Vice-Chancellor, Prof. Frederick Fourie, actually showed us his signature on the screen while we were in Ghent”, said Prof. Koos Bekker of the Department of Public Management at the UFS, who was part of the delegation from the Free State.

The delegation consisted of the Premier, Ms Beatrice Marshoff, and several MECs and senior officials from the Free State provincial government, as well as the mayor, councillors and senior officials of the Mangaung Local Municipality. Several staff members of the UFS were also part of the delegation.

According to Prof. Bekker, the two universities will co-operate in various areas in terms of the memorandum of understanding.

“In the short term the collaboration will be focused on bio-fuels, public management and the digital divide, while discussions in other areas such as health services and organised crime are also under way,” he said.

As part of the memorandum of understanding, the following collaborative efforts are also envisaged:

Mr Lyndon du Plessis, a lecturer in the Department of Public Management, will be enrolled for a Ph.D. at both universities as from September 2008.

A research project involving both universities, the Mangaung Local Municipality and the City of Ghent, will be undertaken.
An investigation will be conducted by both universities regarding the possibility of writing a book on performance management in the public sector (negotiations with the publisher in this regard are under way).

An exchange programme involving students and staff from both universities will be established.

Academics from the UFS delivered papers during one of the forums that formed part of the Accenta Trade Fair programme in Ghent. Prof. Koos Bekker and Mr Lyndon du Plessis from the Department of Public Management delivered papers on strategic planning in practice on the first day of the event, which was devoted to scientific seminars. On the second day Prof. Lucius Botes, Director of the Centre for Development Support at the UFS, delivered a paper on economic development issues, and on the third day Prof. Gustav Visser, Associate Professor in the Department of Geography at the UFS, delivered a paper on tourism.

Papers on bridging the digital divide were presented during the video conference by academics in both Bloemfontein and Ghent.

As guests of honour at the Accenta Trade Fair, the Free State delegation was allocated the main exhibition floor space, covering 1 092 m². The Main Exhibition Hall covers a total surface area of 40 000 m². The Accenta Trade Fair attracts an average of 100 000 visitors annually. The UFS also participated as an exhibitor at the Trade Fair.

This visit was a follow-up of the previous visit, during which the Free State delegation was hosted by the City of Ghent and the provincial government of East Flanders for planning purposes from 14 to 24 April 2007.

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt.stg@ufs.ac.za  
14 November 2007
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept